Physician profile
Michelle Decker
NPI 1942917984
$2,712.23
in general payments reported to CMS, 2019-2025
20 companies · $618 in 2025
The $618 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $330 · 2023: $990 · 2024: $774 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $726.91 | 2022-2025 | Caplyta |
| Abbvie INC. | $283.03 | 2023-2025 | |
| Axsome Therapeutics, INC. | $235.66 | 2023-2025 | Auvelity |
| Alkermes, INC. | $210.33 | 2022-2024 | Lybalvi, Aristada |
| Lundbeck LLC | $176.32 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $175.12 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $154.37 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $145.79 | 2023-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $143.86 | 2023-2024 | Ingrezza |
| Corium, LLC | $125.37 | 2023 | Azstarys |
| Collegium Pharmaceutical, INC. | $112.47 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $63.97 | 2022 | |
| Tris Pharma INC | $40.92 | 2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $22.20 | 2024 | |
| Supernus Pharmaceuticals, INC. | $18.79 | 2025 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.37 | 2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $16.47 | 2025 | Relexxii |
| Merck Sharp & Dohme LLC | $15.88 | 2023 | Belsomra |
| Neuronetics, INC. | $14.83 | 2023 | Neurostar Tms Therapy System |
| Sumitomo Pharma America, INC. | $11.57 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.